Related Experiment Video
Updated: Aug 20, 2025

Studying Proteolysis of Cyclin B at the Single Cell Level in Whole Cell Populations
Published on: September 17, 2012
APC/C CDH1 ubiquitinates STAT3 in mitosis
Debanjan Bhattacharjee1, Sreeram Kaveti1, Nishant Jain1
1Department of Applied Biology, CSIR-Indian Institute of Chemical Technology, Uppal Road, Hyderabad 500007, Telangana State, India; Academy of Scientific and Innovative Research (AcSIR), CSIR-HRDC Campus, Sector 19, Kamala Nehru Nagar, Ghaziabad 201002, Uttar Pradesh, India.
Abstract:
STAT3, an oncogene drives tumor growth and is associated with poor prognosis. However, small molecule-based STAT3 inhibitors were unsuccessful in clinics. Recently, STAT3 degraders that ubiquitinate STAT3 were found to elicit long-lasting anti-tumor responses. Thus, triggering STAT3 ubiquitination in cancers is a better strategy than STAT3 inhibition. However, not much is known about the identity of E3-ligases that ubiquitinate STAT3 in cancers. Therefore, to design better therapies to degrade STAT3, we sought to identify E3-ligases that ubiquitinate STAT3 in cancer cells. To answer this question, we determined the cell cycle-dependent ubiquitination of STAT3 in HEK293T cells and examined the link between STAT3 dephosphorylation and ubiquitination. We found that STAT3 is more strongly ubiquitinated in mitosis than in other phases of the cell cycle. We observed that APC/C CDH1 binds and ubiquitinates STAT3 in mitosis. Further, we also found that inhibiting phosphatases decreases STAT3 ubiquitination. We conclude that APC/C CDH1 ubiquitinates STAT3 in mitosis. We suggest that mitosis can be a potential therapeutic window for treating STAT3-activated cancers.
Insights
Targeting STAT3 ubiquitination, not inhibition, shows promise for cancer therapy. Researchers identified APC/C CDH1 as the E3-ligase responsible for STAT3 ubiquitination during mitosis, suggesting a new therapeutic window.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Signal transducer and activator of transcription 3 (STAT3) is an oncogene implicated in tumor growth and poor prognosis.
- Small molecule STAT3 inhibitors have shown limited clinical success, prompting interest in alternative strategies like STAT3 degraders.
- STAT3 degraders leverage ubiquitination to elicit long-lasting anti-tumor responses, making STAT3 ubiquitination a more effective therapeutic strategy than inhibition.
Purpose of the Study:
- To identify E3-ligases responsible for STAT3 ubiquitination in cancer cells.
- To understand the cell cycle-dependent regulation of STAT3 ubiquitination.
- To explore the relationship between STAT3 dephosphorylation and ubiquitination for improved cancer therapy design.
Main Methods:
- Investigated cell cycle-dependent ubiquitination of STAT3 in HEK293T cells.
- Examined the link between STAT3 dephosphorylation and ubiquitination.
- Identified the E3-ligase complex responsible for STAT3 ubiquitination during mitosis.
Main Results:
- STAT3 ubiquitination is significantly higher during mitosis compared to other cell cycle phases.
- The anaphase-promoting complex/cyclosome (APC/C) with its coactivator CDH1 was identified as the E3-ligase that binds and ubiquitinates STAT3 in mitosis.
- Inhibition of phosphatases led to decreased STAT3 ubiquitination, suggesting a role for dephosphorylation in regulating this process.
Conclusions:
- APC/C CDH1 ubiquitinates STAT3 during mitosis.
- Mitosis represents a potential therapeutic window for targeting STAT3-activated cancers through E3-ligase-mediated degradation.
More Related Videos
07:39Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
08:33Combining Mitotic Cell Synchronization and High Resolution Confocal Microscopy to Study the Role of Multifunctional Cell Cycle Proteins During Mitosis
Published on: December 5, 2017
Related Concept Videos
Anaphase Promoting Complex
Separation of Sister Chromatids
At the onset of anaphase, separase, a proteolytic enzyme, is...
The JAK-STAT Signaling Pathway
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
PI3K/mTOR/AKT Signaling Pathway